PPARactivation is a critical event in luminal muscle-invasive bladder cancer (MIBC) tumorigenesis, favoring both tumor cell growth and microenvironment modulation toward tumor immune escape. Conversely, the down-regulation of PPARactivity in basal MIBC suggests tumor suppressive effects in this subgroup. Here, we report genetic, epigenetic and functional evidence to support the tumor suppressor role for PPAR in basal bladder tumors. We identified hemizygous deletions, DNA hyper-methylation and loss-of-function mutations of PPARin basal MIBC, associated with PPAR under-expression and its decreased activity. Re-expression of PPARin basal tumor cells resulted in the activation of PPAR-dependent transcription program that modulated fatty acid metabolism and cell differentiation and decreased cell growth, which could partly rely on EGFR down-regulation.
Introduction
The nuclear receptor PPAR (peroxisome proliferator-activated receptor gamma) functions as a permissive heterodimer with RXR (retinoid X receptor and recognizes specific sequence motifs, defined as PPRE (peroxisome proliferative response elements), in the regulatory regions of its target genes. In the absence of ligand, PPAR is complexed with corepressor proteins, such as NCoR1 (Nuclear receptor corepressor 1) or SMRT (silencing mediator of retinoic acid receptor), which induces HDAC (histone deacetylase) recruitment, leading to PPARmediated transcriptional repression. Conversely, upon ligand binding, a conformational change allows the release of corepressors and the recruitment of coactivators, such as MED1 (Mediator complex subunit 1) or PGC1 (PPARGC1A, PPARG coactivator 1 alpha), enabling PPAR transcriptional activity. A variety of natural ligands, such as polyunsaturated fatty acid or prostaglandin J2 derivatives, and synthetic ligands, such as thiazolinediones, can activate PPAR. PPAR is involved in the regulation of glucose homeostasis and adipogenesis 1, 2 but also in the differentiation of several tissue types, including the urothelium 3, 4 . Its role in cancer is less clear and seems to be dual, tumor suppressor (in colon, lung cancers and neuroblastoma) or pro-tumorigenic (in pancreatic or bladder cancers), depending on the cell type [5] [6] [7] [8] [9] .
In bladder cancer, the 4 th most frequent cancer in men in industrialized countries, the luminal subtype of muscle-invasive bladder carcinomas (MIBCs), which accounts for 60% of MIBCs 10, 11 , has been shown to display a PPAR activation signature 8, 12 . This activation is associated with genetic alterations which are associated with the luminal subtype, namely PPAR DNA gains and amplifications (30%) or recurrent activating mutations of RXR (5%) or PPAR (4%) 10, [13] [14] [15] [16] . PPAR activation renders bladder tumor cell growth PPARdependent 14, 16 and promotes immune evasion in MIBCs 17 providing evidence for protumorigenic roles of the PPAR/RXR pathway in luminal bladder tumors.
Interestingly, PPAR activation signature or regulon activity is dramatically decreased in basal bladder tumors, a subtype accounting for 35% of MIBCs and presenting a poor prognosis, suggesting that PPAR could display an opposite role in this subtype [10] [11] [12] 18 . In this work, we hypothesized that the loss of PPAR activity could be essential for the tumorigenesis of the basal subtype of MIBCs. We searched for genetic and epigenetic alterations that could drive PPAR inactivation in basal bladder tumors and could support a tumor suppressor role for PPAR. In basal tumors, we identified an enrichment in hemizygous deletions, DNA hyper-methylation and repressive histone mark (H3K9me3) of PPAR, associated with PPAR loss of expression. Among the non-recurrent mutations of PPAR that we previously identified by sequencing PPAR in 359 tumors and studying publicly available data for 455 MIBCs 16 , four mutations were associated with basal tumors.
Functional analysis revealed that these four mutations reduce the transcriptional activity of PPAR. Further biochemical and structure-function analysis of two of these mutations, affecting the ligand-binding domain of PPAR, showed that they alter PPAR activity through the destabilization of helix H12, thereby impairing the release of corepressors and the recruitment of coactivators. Furthermore, induced PPAR expression in basal bladder cancer cell lines activated PPAR-dependent transcription and decreased cell viability, whereas it displayed no effect on cell viability of luminal cells. Finally, we show that the tumor suppressive activity of PPAR in basal tumors could at least partially rely on EGFR downregulation. Our study provides genetic, epigenetic and functional evidence of a tumor suppressive role for PPAR in basal bladder cancer and therefore supports the use of PPAR synthetic agonists as a therapeutic strategy for this subgroup. It reinforces the central role of PPAR in bladder tumorigenesis that appears to be subgroup dependent: protumorigenic in differentiated luminal tumors and tumor suppressor in basal tumors.
Results

Hemizygous deletions, DNA hypermethylation and loss of expression of PPAR associated with basal MIBC
We studied PPAR expression in 197 bladder tumors -101 of which were Non Muscle-Invasive Bladder Cancers (NMIBCs)-in our CIT series of tumors (Carte d'Identité des Tumeurs) using U133 plus 2.0 Affymetrix transcriptomic data 8, 18 and in 405 MIBC samples using publicly available RNAseq data from The Cancer Genome Atlas 10,13 genomic database (http://cancergenome.nih.gov) ( Fig. 1a ). Tumors were grouped in six molecular classes according to a molecular consensus classification derived from six independent classification systems previously described for MIBC 11 ( Supplementary Table 1 ). In good agreement with the loss of transcriptional activity of PPAR observed in basal tumors 10 Conversely, gains and amplifications were associated with overexpression and hyperactivity of PPAR as previously described 8, 9, 14, 16 . We further noticed that these hemizygous deletions were significantly enriched in basal/squamous tumors and could therefore account for part of the loss of expression of PPAR in this subgroup (Fig. 1c ). The genomic deletions of PPAR in basal tumors were a first genomic evidence suggesting a tumor suppressor role for PPAR in these tumors. Since aberrant patterns of DNA methylation can also affect tumor suppressor gene expression during tumorigenesis, we analyzed PPAR DNA methylation in 368 MIBCs using DNA methylation array data available from TCGA. We identified a significant hyper-methylation of PPAR CpGs in basal tumors compared to luminal ones, mostly in shore regions of CpG islands within the PPAR promoter ( Fig.1d , upper panel and supplementary Fig.1a ). The hyper-methylation, which correlated with the downregulation of PPARexpression in basal tumors (Fig.1d , middle and lower panels), could also account for part of its loss of expression in basal tumors. These results were further validated in our CIT series of tumors ( Supplementary Fig.1b ). We also observed an enrichment of histone repressive mark (H3K9me3) in PPAR regulatory regions in two basal (L1207 and 5367) as compared to two luminal bladder cancer cell lines (RT112 and SD48) ( Supplementary   Fig.1c ). These data provided epigenetic evidences supporting the tumor suppressor role of PPAR in basal tumors.
Loss-of-function mutations of PPARG in basal tumors
Loss-of-function mutations are also a hallmark of tumor suppressor genes. We therefore searched for such alterations of PPAR in basal bladder tumors. We previously sequenced PPAR in 359 bladder tumors and studied publicly available data for 455 MIBCs, which allowed us to identify recurrent activating mutations of PPAR in 4% of bladder tumors 16 .
These mutations were enriched in tumors presenting a high PPAR activation score, which were mostly luminal tumors, supporting the protumorigenic role of PPAR in this subgroup.
We had also identified eleven non-recurrent PPAR mutations that we did not further study 16 ( Fig. 2a ). Here, we numbered all mutations relative to the PPARγ2 isoform (NM_015869), which is 28 amino acids longer than the PPARγ1 isoform (NM_138712) at the N-terminal end ( Fig. 2a ). Four of these non-recurrent mutations, S74C, F310S, E455Q and H494Y, were associated with basal tumors which presented a low PPAR activation score ( Fig. 2b ).
We therefore hypothesized that these four mutations could be loss-of-function mutations and investigated their functional impact on the transcriptional activity of PPAR ( Fig. 2c and   2d ). We used, in HEK293FT cells, a luciferase reporter gene containing three copies of the DR1 sequence of the PPRE arranged in tandem and linked to the thymidine kinase promoter (PPRE-3X-TK) 19 . The four PPARγ mutant proteins had significantly lower levels of transcriptional activity than the wild type even in the presence of rosiglitazone, a synthetic PPARγ agonist (activity reduced by 25% to 90%) ( Fig. 2c ). We further focused on the two most inactive mutants that affect the ligand binding domain (LBD) of PPAR, F310S and H494Y. We showed that their overexpression in the basal bladder cell line 5637 induced a significantly lower expression of several known PPARγ target genes (FABP4 and ACSL5) compared to the wild-type protein as shown by RT-qPCR ( Fig. 2d ). The effects of the mutants were comparable to that of the empty plasmid, suggesting an absence of transcriptional activity of the proteins in this system. The results of these two different approaches to measure PPAR transcriptional activity clearly showed that PPAR mutations F310S and H494Y are loss-of-function mutations affecting basal tumors.
Loss-of-function mutations impair the release of corepressors and recruitment of coactivators by PPAR in the presence of ligand.
We then performed biochemical and biophysical analyses to understand how these two mutations impair PPARγ activity. F310S is located in the N-ter of helix 3 facing the loop between helices 11 and 12 whereas the H494Y mutation involves a residue at the N-terminal boundary of helix 12 ( Fig. 3a ). Native electrospray mass spectrometry indicated that the purified recombinant LBD wild-type and mutants ( Supplementary Figs. 2-3) were not bound to any ligand ( Supplementary Fig. 4 ). We used nano differential scanning fluorimetry to compare the thermal stability of the purified PPARγ WT and mutants, alone and upon binding to the agonist ligand, GW1929 ( Supplementary Fig. 2c ). The two mutants in their apo form exhibited a lower melting temperature (Tm) than the WT with a Tm of 1°C and 2°C for F310S and H494Y, respectively. Of note, GW1929 induced a strong stabilization of the WT, as well as of the 2 mutants, suggesting that the 2 mutations do not significantly affect the binding of GW1929. Both mutants efficiently formed heterodimers with RXR similarly to PPAR wild-type ( Supplementary Fig. 2b ). We therefore focused on the ability of mutations to modulate PPAR binding to corepressors and coactivators, which involves recognition of motifs on coregulators by the LBD, and ultimately regulates the transcriptional output of target genes. To study the binding of PPARto corepressor and coactivator proteins, we performed mammalian two-hybrid assay in HEK293FT cells, using VP16-fused PPAR (wild-type, F310S and H494Y), GAL4-DNA-binding-domain-fused co-repressor (NCoR1 or SMRT) or co-activator MED1 and pG5-LUC reporter. We showed that in the context of full protein and in presence of exogenous ligand (rosiglitazone), the two mutations significantly favored the binding of the two co-repressor peptides and inhibited the recruitment of MED1 coactivator domain compared to PPARγ wild-type ( Fig. 3b ). The lower recruitment of the coactivator and increased recruitment of the corepressors by the two mutants was confirmed by monitoring coregulator peptide recruitment by the different LBDs ( Fig.3c ). We measured the interaction between wild-type or mutant forms of PPARγ and a fluorescently labeled coactivator peptide of PGC1α (PPARGC1A) or a fluorescent labeled NCoR1 corepressor peptide, by MicroScale Thermophoresis. In the absence of ligand, the WT recruited the coactivator peptide with higher affinity than the two mutants ( Fig. 3c ). The addition of a full agonist, rosiglitazone ( Supplementary Fig. 5 ), enhanced the interaction between PPAR and PGC1α coactivator peptide, with the WT exhibiting again the highest affinity. On the other hand, the 2 mutants exhibited increased affinity for the corepressor peptide of NCoR1 compared to WT (Fig. 3c ). The increased interaction with corepressor and decreased interaction with coactivator of the mutants was also observed by native mass spectrometry (Supplementary Figs. 6-8). Together, these data suggest that the two considered mutations, F310S and H494Y, impair the adoption of an agonist conformation by PPARγ in the presence of ligand, thereby enhancing corepressor interactions and inhibiting coactivator interaction.
PPAR LBD mutations F310S and H494Y favor an inactive conformation
To elucidate the structural basis for the deleterious functional effects of the mutations, we analyzed the crystal structures of PPARγ LBD F310S and H494Y (Supplementary Table   2 ). PPARγ F310 LBD mutant was crystallized in complex with GW1929 and PPAR H494Y LBD in complex with GW1929 and the PGC1coactivator peptide. Although the two mutants were less active than the wild-type protein, the ligand and/or coactivator peptide concentration used for crystallization allowed the proteins complexes to be crystallized in an active conformation. The GW1929 agonist ligand in the two mutant complexes maintained the same position as the WT complex forming similar interactions 16 with the exception, in the F310S mutant, of the presence of two water molecules as a consequence of a larger binding pocket ( Supplementary Fig. 9 ).
In the WT complex, H494 in helix 12 packs on top of V318 (H3) and forms intra-helical interactions with P495 and L496 that both contribute to a hydrophobic surface on which the coactivator packs ( Fig. 4a ). In the H494Y mutant, the side chain pointed toward loop 2-3 and the side interactions with P495 and L496 were lost suggesting a destabilization of helix 12. Due to the Y494 side chain re-orientation, Y494 forms new interactions with residues F315 (H3) and F292 and H294 (loop 2-3) of the mutant.
In the other mutant of interest, the bulky F310 side chain faces the loop 11-12 and is involved in van der Waals interactions with F388 (H7), I484 (H11) and M491 (loop [11] [12] .
Because of the smaller size of the S310 side chain, these interactions are lost ( Fig. 4b ) and
induce a more flexible conformation of the loop 11-12. In contrast S310 hydroxyl group interacts with the carbonyl moiety of Q311 and a water molecule. These variations in helix 11 and loop11-12 interactions will result in H12 destabilization and less efficient recruitment of coactivator. Overall, these data suggest that the two studied mutations, F310S and H494Y, are important residues for proper stabilization of helix 12 of PPARγ, preventing proper corepressor release and coactivator interaction.
PPAR displays an inhibitory effect on basal bladder cancer cells growth
The down-regulation of PPAR in basal tumors suggested a potential tumor suppressive activity of PPAR in these tumors. The association of PPAR downregulation with PPAR genomic deletions, DNA hypermethylation and of loss-of-function mutations, although rare events in basal tumors (observed in 4 out of 188 basal tumors, Fig. 2b ), strongly reinforced this hypothesis. Activation of PPAR by synthetic agonists has been a matter of debate regarding the PPAR independent-effects of such molecules 20 . Therefore, to study the ability of PPAR activation to inhibit basal bladder cancer cell proliferation, we transiently expressed PPARin three cell lines presenting a low PPAR activation score and a low PPAR expression level (UMUC-3, unclassified; UMUC-6 and VMCUB-1, Basal/Squamous cell lines), as well as in one luminal papillary cell line, SD48, which diplays a high expression level of PPAR, a high PPAR activation score and relies on PPAR expression for its growth 8 ( Fig. 5a and 5b) . PPAR overexpression, observed by western-blot or RT-qPCR analysis ( Supplementary Fig. 10a and 10c ), activated a PPAR-dependent transcription program ( Supplementary Fig. 10a ) in the four cell lines. PPAR overexpression induced a significant decrease in cell viability in the three cell lines expressing low levels of endogenous PPAR, but did not affect the growth of SD48 cells (Figure 5b ). Using UMUC-6 basal cells, we confirmed that the observed effects with the wild-type receptor or the activating mutation T475M were dependent on PPAR activity since the overexpression of the inactive mutant of PPAR, H494Y, had no effect neither on cell viability nor on PPAR target gene expression ( Fig. 5c and supplementary Fig. 10a -c). The tumor supressive role of PPAR in basal tumors was further supported by our attempt to establish stable clones of basal UMUC-6 cells. We were only able to obtain a few clones with the wild-type or T475M PPAR constructs, which turned out not to express PPAR, whereas we obtained PPAR-expressing clones using H494Y PPAR construct ( Supplementary Fig. 10d ). To better understand the molecular mechanisms underlying this tumor suppressive property of PPAR, we compared UMUC-6 transcriptomic data after transient transfection using either a control backbone or a PPAR encoding plasmid. We identified 459 differentially expressed genes using LIMMA algorithm and considering a p-value<0.05 (Supplementary table 3 ).
Analysis of the biological processes enriched in these genes using DAVID software highlighted that, as previously observed in luminal bladder cell lines, PPAR expression induced an increased lipid metabolism 8, 9, 14 and impaired immunity and inflammation 15 .
However, PPAR expression also induced a down-regulation of two sets of genes favoring cell proliferation and inhibiting apoptosis (Fig.5d ). The regulation of these two process by PPAR could account for the inhibition of cell viability induced upon PPAR expression in basal cell lines. Focussing on the list of urothelial differentiation markers recently provided by Liu et al. 4 , we also confirmed the role of PPARG in inducing differentiation (Fig. 5e ).
However, as described by Warrick et al. 21 , PPAR expression alone is not sufficient to transduce basal cells into luminal ones according to our consensus classifier for cell lines.
We also performed a GSEA analysis of regulated genes using Reactome database which highlighted the up-regulation of "fatty acid metabolism" and "fatty acid beta oxydation" as well as an increase of "FOXO-mediated transcription of cell death genes". A potential involvement of the EGFR pathway in the regulation of cell growth was suggested by the down-regulation of "GRB2 events in EGFR signaling", which included a downregulation in gene expression of EGFR and its ligands EREG and EPGN (Supplementary Figure 11 ). We further validated this finding at the protein level by western-blot in UMUC-6, VMCUB1 and UMUC-3: PPAR expression induced a down regulation of Aurora B, AXL and EGFR levels, which could regulate cell proliferation and apoptosis (Fig.5f ). The down-regulations likely relied on PPAR activity since they were stronger after the expression of the active mutant of PPAR T475M but not observed after the expression of the inactive mutant PPAR H494Y ( Fig.5f , UMUC-6 cells).
Discussion
Previous studies have suggested a tumor suppressor role for PPAR in bladder cancer, based on its observed down-regulation in a subset of tumors and on the inhibitory effects of PPAR agonist on bladder cancer cell lines in vitro and in vivo [22] [23] [24] [25] . Simvastatin-induced inhibition of bladder cancer cell growth was also attributed to the activation of the PPAR pathway, further supporting its tumor suppressor role in bladder tumors 26 . In this study, we provided epigenetic, genetic and functionnal evidence to demonstrate the tumor suppressor role for PPAR and we associated this role to a particular subgroup of tumors, the basal subtype. In order to demonstrate its tumor suppressive properties, we overexpressed PPARin basal or unclassified cell lines expressing low levels of PPAR, including UMUC-3 cells in which PPAR expression induced comparable results to those observed recently using agonists 23 . These finding suggest that the observed effects using agonist molecules were more likely PPAR-dependent. In addition, the other cell lines for which PPAR agonists have been shown to induce cell growth inhibition [22] [23] [24] [25] happened to be unclassified or basal using our consensus molecular classifier and thus supports the use of PPAR synthetic agonists as a therapeutic option for basal tumors. The possible reactivation of PPAR in basal tumors by agonists despite low expression levels in tumors presenting hemizygous deletions and/or promoter hypermethylation, and the fact that inactivating mutations did not seem to display dominant negative effects are in favor of an haploinsufficiency of PPAR. This mechanism of action of PPAR has already been suggested in lipodystrophy 27 . A better understanding of the molecular basis of the tumor suppressive activity of PPAR in basal bladder tumors may lay the groundwork to propose alternative therapeutic strategies to indirectly target the PPARpathway, in order to avoid various side effects induced by the available PPARsynthetic agonists 28, 29 . We previsouly showed that basal tumors present an activation of the EGFR pathway and rely on EGFR activity for their growth in vitro and in vivo 18 . Here, we showed that PPAR overexpression in basal cell lines induces a down-regulation of EGFR and its ligands, which was, at least for EGFR, dependent on PPAR activity, since not observed upon the overexpression of the inactive mutant of PPARG, H494Y. These results suggest that the decreased cell viability induced by PPARoverexpression may be partly EGFR-mediated. A tumor suppressor role for PPAR has already been reported for several cancer types including colon, lung, breast and ovarian cancers, but the relationship with the EGFR pathway has not been reported in these cancers. So far, the tumor suppressive properties of PPAR have been more linked to antiangiogenic effects 30 or to an increase in reactive oxygen species (ROS) level due to a metabolic switch induced by PPAR 31 . The modulation of fatty acid metabolism and mitochondrial beta-oxydation by PPAR in basal bladder cancer cell could also contribute to its tumor suppressive activities. In vivo studies should allow studying the impact of PPAR expression on angiogenesis and the tumor microenvironment and their contribution on tumor growth. Inactivating mutations, altough not frequent, seem to be bladder cancer-specific, but deletions or methylation appear to be the main causes of PPAR loss of activity. Inactivating mutations were initially reported in colon cancer but remain controversial since they have never been observed in independent cohorts 32 . A better knowledge of the structure/function effects of the loss-of-function mutation of PPAR could also guide the design of new potent and more specific agonists.
Together with our previous studies that put forth the pro-tumorigenic role of PPARassociated with DNA amplification and gain-of-function mutations 8, 16 in luminal tumors, this study highlights a dual role of PPAR in bladder cancers. The therapeutic strategies targeting PPAR should therefore be tumor subtype-dependent, strengthening the interest for the application of the molecular classification in the clinic. The dual role of PPAR also suggest that the risk of bladder cancer associated with the use of pioglitazone 33, 34 should be associated with the development of luminal tumors. The cell context dependent effect of PPAR has already been shown in breast and colon cancer [35] [36] [37] . A better understanding of the signaling pathways activated by the receptor to mediate both its pro-tumorigenic and tumor suppressive effects should help further our understanding of the relation between cell context, in particular cell differentiation, and PPAR activity in bladder cancer but also in other tumor types. Transcriptomic, genomic, methylation and ChIPseq data. We used transcriptomic data available for our CIT series of tumors 8, 18 and for 405 MIBC from TCGA (http://cancergenome.nih.gov). We used our affymetrix exon st.0 and U133 plus2.0 transcriptomic data 18 available for RT112, L1207, VMCUB-1, UMUC-3, UMUC-6 cell lines.
Methods
Materials
Tumors and cell lines were classified using a molecular consensus classification system 11 and PPARG activation score were calculated as previously described taking into consideration the expression levels of 77 PPARG target genes 16 . We used publicly available copy number data for 402 MIBC from TCGA (http://cancergenome.nih.gov). We used methylation data (450k methylation array) available for 368 MIBC from TCGA and for 59 samples from our CIT series. We used histone marks (H3K27ac, H3K9me3) ChIPseq data for RT112, SD48 and L12017 and 5637 cell lines available in the GEO database: GSE104804 and GSE140891. Horseradish peroxidase-conjugated anti-mouse IgG (Cell Signaling Technology # 7074, used at 1/3,000) was used as the secondary antibody. Protein loading was checked by staining the membrane with Amido Black after electroblotting.
Real-time reverse transcription-quantitative PCR. Reverse transcription was
performed with 1 µg of total RNA, and a high-capacity cDNA reverse transcription kit (Applied Biosystems). cDNAs were amplified by PCR in a Roche real-time thermal cycler, with the Roche Taqman master mix (Roche) and Taqman probe/primer pairs that we previously used and described 16 . Relative gene expression was analyzed by the delta delta Ct method, with TBP as the reference. Supplementary Fig.2) .
Crystallization, X-ray data collection and crystal structure refinement. The The structure was solved by molecular replacement in PHASER 41 and refined with PHENIX 42 and BUSTER 43 with TLS refinement, followed by iterative model building in COOT 44 .
Crystals of PPAR F310S-GW1929 were grown in 25% PEG3350, 0.2 M LiSO4, BisTris 0.1M pH 6.5, transferred to artificial mother liquor containing 35% PEG3350 and flashcooled in liquid nitrogen. X-ray diffraction data were collected at PX1 beamline of the SOLEIL synchrotron with a wavelength of 0.979 Å. The final structure was refined to Rwork and Rfree values of 16.8 and 20.6%, respectively, with excellent geometry (97.27% of residues in favored region of the Ramachandran plot and 2.73% in the allowed region).
Crystals of PPAR H494Y-GW1929-PGC1α were grown in 0.2 M ammonium acetate, 0.1 M Hepes pH 7.5, trisodium citrate 1.2M, transferred to artificial mother liquor containing 15% glycerol and flash-cooled in liquid nitrogen. X-ray diffraction data were collected at the ID30A3 beamline of ESRF with a wavelength of 0.968 Å. The final structure was refined to Rwork and Rfree values of 17.22 and 20.30%, respectively, with excellent geometry (97.81 % of residues in favored region of the Ramachandran plot and 2.19% in the allowed region).
Data collection and refinement statistics are provided in Supplementary Table 1 . GW1929 and side chains of the mutated residues of H494Y and F310S complexes could be modelled with confidence as shown into the Polder omit maps 45 displaying reduced model bias and exclusion of solvent molecules ( Supplementary Fig. 3b and 3c ). All structural figures were prepared with PyMOL (www.pymol.org/). 
Microscale thermophoresis
Affymetrix DNA array
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